Ewing sarcoma · 11 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
TC, then IE, VDoxoC, VEC | — | R 122 939 | 21d | — | — | ~3 | ~R 204 248 indirect | — |
VAI Variant #02 | — | R 48 879 | 21d | — | — | ~3 | ~R 146 638 indirect | — |
VAdCA/IE N/A - protocol | — | R 35 402 | 21d | — | — | ~9 | ~R 296 490 indirect | — |
IE Variant #01 | — | R 22 128 | 21d | — | — | ~12 | ~R 265 533 indirect | — |
VIDE Variant #01 | — | R 21 578 | 21d | — | — | ~6 | ~R 129 465 indirect | — |
VAdCA N/A - protocol | — | R 13 274 | 21d | — | — | ~17 | ~R 225 662 indirect | — |
ICE Variant #05 | — | R 12 735 | — | — | ~13.9 mo | ~4 | ~R 50 942 PFS proxy · indirect | — |
Cyclophosphamide and Topotecan Variant #03 | — | R 11 936 | — | — | — | ~15 | ~R 179 033 indirect | — |
Docetaxel and Gemcitabine Variant #01 | — | R 6 266 | 21d | ~6.2 mo | — | ~9 | ~R 56 391 PFS proxy · indirect | 1 |
Busulfan and Melphalan Variant #01 | — | R 5 951 | — | — | — | ~1 | ~R 5 951 PFS proxy · indirect | 1 |
Irinotecan and Temozolomide Variant #01 | — | R 5 470 | 28d | — | — | ~2 | ~R 10 941 indirect | — |
11 of 11 regimens shown